Carlos Fernando Mendoza, Jose Luis Huerta, Iustina Chirila, Dania Abreu, Moe H Kyaw, Benjamin Yarnoff
{"title":"在墨西哥对使用适应性COVID-19疫苗的疫苗接种策略的潜在公共卫生和经济影响以及成本效益进行建模。","authors":"Carlos Fernando Mendoza, Jose Luis Huerta, Iustina Chirila, Dania Abreu, Moe H Kyaw, Benjamin Yarnoff","doi":"10.1080/14760584.2025.2505087","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the impact of vaccination strategies using an adapted COVID-19 vaccine in Mexico.</p><p><strong>Research design and methods: </strong>This study used a previously published combined Markov-decision tree model adapted for the Mexican context. The base case examined the population aged ≥ 65 years and the high-risk population (defined as those with one or more comorbidities associated with high risk of severe disease) aged 12-64 years. Scenario analyses examined lower age cutoffs for eligibility in the standard risk population (≥50 years, ≥18 years, and ≥12 years). Sensitivity analyses varying the parameters by ± 20% was conducted to assess uncertainty.</p><p><strong>Results: </strong>Compared to no vaccination, the base case was estimated to prevent 1,509,194 cases, 132,166 hospitalizations 24,575 deaths, and 276,223 lost quality-adjusted life-years (QALYs), increasing direct costs by $602,446,820 and decreasing societal cost by $2,264,266,271. The ICER was dominant from the societal perspective and $2,181 from the payer perspective, which was cost-effective at a willingness-to-pay threshold of 1× GDP per capita ($11,812). The benefits were further increased in scenarios expanding vaccination to additional age groups.</p><p><strong>Conclusions: </strong>Vaccination strategies targeting a broader age range with an adapted vaccine would result in considerable health and economic benefits and be cost-effective in Mexico.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"393-402"},"PeriodicalIF":5.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in Mexico.\",\"authors\":\"Carlos Fernando Mendoza, Jose Luis Huerta, Iustina Chirila, Dania Abreu, Moe H Kyaw, Benjamin Yarnoff\",\"doi\":\"10.1080/14760584.2025.2505087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study evaluated the impact of vaccination strategies using an adapted COVID-19 vaccine in Mexico.</p><p><strong>Research design and methods: </strong>This study used a previously published combined Markov-decision tree model adapted for the Mexican context. The base case examined the population aged ≥ 65 years and the high-risk population (defined as those with one or more comorbidities associated with high risk of severe disease) aged 12-64 years. Scenario analyses examined lower age cutoffs for eligibility in the standard risk population (≥50 years, ≥18 years, and ≥12 years). Sensitivity analyses varying the parameters by ± 20% was conducted to assess uncertainty.</p><p><strong>Results: </strong>Compared to no vaccination, the base case was estimated to prevent 1,509,194 cases, 132,166 hospitalizations 24,575 deaths, and 276,223 lost quality-adjusted life-years (QALYs), increasing direct costs by $602,446,820 and decreasing societal cost by $2,264,266,271. The ICER was dominant from the societal perspective and $2,181 from the payer perspective, which was cost-effective at a willingness-to-pay threshold of 1× GDP per capita ($11,812). The benefits were further increased in scenarios expanding vaccination to additional age groups.</p><p><strong>Conclusions: </strong>Vaccination strategies targeting a broader age range with an adapted vaccine would result in considerable health and economic benefits and be cost-effective in Mexico.</p>\",\"PeriodicalId\":12326,\"journal\":{\"name\":\"Expert Review of Vaccines\",\"volume\":\" \",\"pages\":\"393-402\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14760584.2025.2505087\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2505087","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in Mexico.
Background: This study evaluated the impact of vaccination strategies using an adapted COVID-19 vaccine in Mexico.
Research design and methods: This study used a previously published combined Markov-decision tree model adapted for the Mexican context. The base case examined the population aged ≥ 65 years and the high-risk population (defined as those with one or more comorbidities associated with high risk of severe disease) aged 12-64 years. Scenario analyses examined lower age cutoffs for eligibility in the standard risk population (≥50 years, ≥18 years, and ≥12 years). Sensitivity analyses varying the parameters by ± 20% was conducted to assess uncertainty.
Results: Compared to no vaccination, the base case was estimated to prevent 1,509,194 cases, 132,166 hospitalizations 24,575 deaths, and 276,223 lost quality-adjusted life-years (QALYs), increasing direct costs by $602,446,820 and decreasing societal cost by $2,264,266,271. The ICER was dominant from the societal perspective and $2,181 from the payer perspective, which was cost-effective at a willingness-to-pay threshold of 1× GDP per capita ($11,812). The benefits were further increased in scenarios expanding vaccination to additional age groups.
Conclusions: Vaccination strategies targeting a broader age range with an adapted vaccine would result in considerable health and economic benefits and be cost-effective in Mexico.
期刊介绍:
Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review.
The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.